New hope for tiniest babies: testing common asthma drug for premature lungs
NCT ID NCT07101640
Summary
This study aims to find the right dose and check the safety of montelukast, a drug used for asthma, in very premature, critically ill infants who are at high risk for developing a serious chronic lung condition called Bronchopulmonary Dysplasia (BPD). It will involve 28 infants who will receive either the drug or a placebo for 7 days. Researchers will closely monitor how the infants' bodies process the drug and track their health and development for up to two years to see if it helps their breathing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRITICAL ILLNESS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.